Search Results
You are looking at 1 - 6 of 6 items for
- Author: Thorvardur R Halfdanarson x
- Refine by access: All content x
Search for other papers by Alaa Sada in
Google Scholar
PubMed
Search for other papers by Travis J McKenzie in
Google Scholar
PubMed
Search for other papers by Adrian Vella in
Google Scholar
PubMed
Search for other papers by Michael J Levy in
Google Scholar
PubMed
Search for other papers by Thorvardur R Halfdanarson in
Google Scholar
PubMed
Localized insulinoma is an uncommon entity that can result in substantial morbidity due to the associated hypoglycemia. Recent studies have suggested an increase in the incidence of insulinoma in recent decades that may possibly be secondary to increased awareness, incidental diagnoses, and better diagnostic methods. Diagnosing and localizing insulinoma within the pancreas can be challenging, but advances in nuclear imaging may improve diagnostic accuracy. Delays in diagnosis are common, but once a localized insulinoma is diagnosed and appropriately treated, the long-term prognosis is excellent. Surgical resection is considered the standard of care management option for localized insulinoma, but tumor ablation with endoscopic ultrasound guidance has also been shown to be an effective and safe method for therapy.
Search for other papers by Thorvardur R Halfdanarson in
Google Scholar
PubMed
Search for other papers by Joseph Rubin in
Google Scholar
PubMed
Search for other papers by Michael B Farnell in
Google Scholar
PubMed
Search for other papers by Clive S Grant in
Google Scholar
PubMed
Search for other papers by Gloria M Petersen in
Google Scholar
PubMed
Pancreatic endocrine tumors (PETs) are uncommon tumors with an annual incidence <1 per 100 000 person-years in the general population. The PETs that produce hormones resulting in symptoms are designated as functional. The majority of PETs are non-functional. Of the functional tumors, insulinomas are the most common, followed by gastrinomas. The clinical course of patients with PETs is variable and depends on the extent of the disease and the treatment rendered. Patients with completely resected tumors generally have a good prognosis, and aggressive surgical therapy in patients with advanced disease may also prolong survival. The epidemiology, prognosis, and established and novel prognostic markers of PETs are reviewed.
Search for other papers by Mojun Zhu in
Google Scholar
PubMed
Search for other papers by Karl R Sorenson in
Google Scholar
PubMed
Search for other papers by Rebecca Liu in
Google Scholar
PubMed
Search for other papers by Bonnie E Gould Rothberg in
Google Scholar
PubMed
Search for other papers by Thorvardur R Halfdanarson in
Google Scholar
PubMed
Pancreatic neuroendocrine tumors (PNETs) encompass a diverse group of malignancies marked by histological heterogeneity and highly variable clinical outcomes. We performed a systematic review on potential prognostic biomarkers in PNETs by searching the PubMed database. A total of 472 manuscripts were reviewed in detail, of which 52 multivariate studies met the inclusion criteria proposed by the Reporting Recommendations for Tumor Marker Prognostic Studies. These altogether analyzed 53 unique targets, and 36 of them were statistically associated with survival.
Division of Pulmonary and Critical Care Medicine, Asante Health System, Medford, Oregon, USA
Search for other papers by Bilal F Samhouri in
Google Scholar
PubMed
Search for other papers by Thorvardur R Halfdanarson in
Google Scholar
PubMed
Search for other papers by Chi Wan Koo in
Google Scholar
PubMed
Department of Respiratory Medicine, St Vincent’s University Hospital, Elm Park, Dublin, Ireland
Search for other papers by Cormac McCarthy in
Google Scholar
PubMed
Search for other papers by Eunhee S Yi in
Google Scholar
PubMed
Search for other papers by Charles F Thomas in
Google Scholar
PubMed
Search for other papers by Jay H Ryu in
Google Scholar
PubMed
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare, but increasingly recognized entity that primarily affects middle-aged and elderly women. It is characterized by abnormal proliferation of pulmonary neuroendocrine cells (PNECs) and is considered a preinvasive lesion for carcinoid tumorlets/tumors. Sometimes, DIPNECH is accompanied by constrictive bronchiolitis which usually manifests as chronic cough and/or dyspnea, along with airflow limitation on spirometry. The telltale imaging sign of DIPNECH is the presence of multiple noncalcified pulmonary nodules and mosaic attenuation on CT. However, these clinico-radiologic features of DIPNECH are characteristic but nonspecific; thus, histopathologic confirmation is usually necessary. DIPNECH has an indolent course and only rarely leads to respiratory failure or death; progression to overt neuroendocrine tumor (carcinoid) of the lung occurs in a minority of patients. Of available therapies, somatostatin analogs and mechanistic target of rapamycin inhibitors are the most promising. In this review, we provide an update regarding the diagnosis and management of DIPNECH and describe critical gaps in our understanding of this entity, including the central terms ‘diffuse’ and ‘idiopathic.’ We also summarize the inconsistencies in definitions employed by recent studies and discuss the pitfalls of the DIPNECH definitions proposed by the World Health Organization in 2021. In this context, we propose an objective and reproducible radio-pathologic case definition intended for implementation in the research realm and seeks to enhance homogeneity across cohorts. Furthermore, we discuss aspects of PNECs biology which suggest that PNEC hyperplasia may contribute to the pathogenesis of phenotypes of lung disease aside from constrictive bronchiolitis and carcinoid tumorlets/tumors. Finally, we steer attention to some of the most pressing and impactful research questions awaiting to be unraveled.
Search for other papers by Jennifer R Eads in
Google Scholar
PubMed
Search for other papers by Thorvardur R Halfdanarson in
Google Scholar
PubMed
Search for other papers by Tim Asmis in
Google Scholar
PubMed
Search for other papers by Andrew M Bellizzi in
Google Scholar
PubMed
Search for other papers by Emily K Bergsland in
Google Scholar
PubMed
Search for other papers by Arvind Dasari in
Google Scholar
PubMed
Search for other papers by Ghassan El-Haddad in
Google Scholar
PubMed
Search for other papers by Michael Frumovitz in
Google Scholar
PubMed
Search for other papers by Joshua Meyer in
Google Scholar
PubMed
Search for other papers by Erik Mittra in
Google Scholar
PubMed
Search for other papers by Sten Myrehaug in
Google Scholar
PubMed
Search for other papers by Eric Nakakura in
Google Scholar
PubMed
Search for other papers by Nitya Raj in
Google Scholar
PubMed
Search for other papers by Heloisa P Soares in
Google Scholar
PubMed
Search for other papers by Brian Untch in
Google Scholar
PubMed
Search for other papers by Namrata Vijayvergia in
Google Scholar
PubMed
Search for other papers by Jennifer A Chan in
Google Scholar
PubMed
High-grade neuroendocrine neoplasms are a rare disease entity and account for approximately 10% of all neuroendocrine neoplasms. Because of their rarity, there is an overall lack of prospectively collected data available to advise practitioners as to how best to manage these patients. As a result, best practices are largely based on expert opinion. Recently, a distinction was made between well-differentiated high-grade (G3) neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas, and with this, pathologic details, appropriate imaging practices and treatment have become more complex. In an effort to provide practitioners with the best guidance for the management of patients with high-grade neuroendocrine neoplasms of the gastrointestinal tract, pancreas, and gynecologic system, the North American Neuroendocrine Tumor Society convened a panel of experts to develop a set of recommendations and a treatment algorithm that may be used by practitioners for the care of these patients. Here, we provide consensus recommendations from the panel on pathology, imaging practices, management of localized disease, management of metastatic disease and surveillance and draw key distinctions as to the approach that should be utilized in patients with well-differentiated G3 neuroendocrine tumors vs poorly differentiated neuroendocrine carcinomas.
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
Molecular Medicine Program, University of Pavia, Pavia, Italy
Search for other papers by Lorenzo Gervaso in
Google Scholar
PubMed
Search for other papers by Thorvardur R Halfdanarson in
Google Scholar
PubMed
Search for other papers by Mohamad Sonbol in
Google Scholar
PubMed
Search for other papers by Rachel A Eiring in
Google Scholar
PubMed
Search for other papers by Sara Pusceddu in
Google Scholar
PubMed
Search for other papers by Natalie Prinzi in
Google Scholar
PubMed
Search for other papers by Benedetta Lombardi Stocchetti in
Google Scholar
PubMed
Search for other papers by Simona Grozinsky-Glasberg in
Google Scholar
PubMed
Search for other papers by David J Gross in
Google Scholar
PubMed
Search for other papers by Thomas Walter in
Google Scholar
PubMed
Search for other papers by Patrick Robelin in
Google Scholar
PubMed
Search for other papers by Catherine Lombard-Bohas in
Google Scholar
PubMed
Search for other papers by Samuele Frassoni in
Google Scholar
PubMed
Search for other papers by Vincenzo Bagnardi in
Google Scholar
PubMed
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Search for other papers by Lorenzo Antonuzzo in
Google Scholar
PubMed
Search for other papers by Clotilde Sparano in
Google Scholar
PubMed
Search for other papers by Sara Massironi in
Google Scholar
PubMed
Search for other papers by Fabio Gelsomino in
Google Scholar
PubMed
Search for other papers by Alberto Bongiovanni in
Google Scholar
PubMed
Search for other papers by Nicoletta Ranallo in
Google Scholar
PubMed
Search for other papers by Salvatore Tafuto in
Google Scholar
PubMed
Search for other papers by Maura Rossi in
Google Scholar
PubMed
Search for other papers by Mauro Cives in
Google Scholar
PubMed
Search for other papers by Ibrahim Rasul Kakil in
Google Scholar
PubMed
Search for other papers by Hytam Hamid in
Google Scholar
PubMed
Search for other papers by Alessandra Chirco in
Google Scholar
PubMed
Search for other papers by Michela Squadroni in
Google Scholar
PubMed
Search for other papers by Anna La Salvia in
Google Scholar
PubMed
Search for other papers by Jorge Hernando in
Google Scholar
PubMed
Search for other papers by Johannes Hofland in
Google Scholar
PubMed
Search for other papers by Anna Koumarianou in
Google Scholar
PubMed
Search for other papers by Sabrina Boselli in
Google Scholar
PubMed
Search for other papers by Darina Tamayo in
Google Scholar
PubMed
Search for other papers by Cristina Mazzon in
Google Scholar
PubMed
Search for other papers by Manila Rubino in
Google Scholar
PubMed
Search for other papers by Francesca Spada in
Google Scholar
PubMed
We conducted a retrospective/prospective worldwide study on patients with neuroendocrine neoplasms (NENs) and a molecularly proven SARS-CoV-2 positivity. Preliminary results regarding 85 patients of the INTENSIVE study have been published in 2021. Now we are reporting the 2-year analysis.Here, we are reporting data from consecutive patients enrolled between 1 June 2020, and 31 May 2022. Among the 118 contacted centers, 25 were active to enroll and 19 actively recruiting at the time of data cut-off for a total of 280 patients enrolled. SARS-CoV-2 positivity occurred in 47.5% of patients in 2020, 35.1% in 2021, and 17.4% in 2022. The median age for COVID-19 diagnosis was 60 years. Well-differentiated tumors, non-functioning, metastatic stage, and gastroenteropancreatic (GEP) primary sites represented most of the NENs. COVID-19-related pneumonia occurred in 22.8% of the total, with 61.3% of them requiring hospitalization; 11 patients (3.9%) needed sub-intensive or intensive care unit therapies and 14 patients died (5%), in 11 cases (3.9%) directly related to COVID-19. Diabetes mellitus and age at COVID-19 diagnosis > 70 years were significantly associated with COVID-19 mortality, whereas thoracic primary site with COVID-19 morbidity. A significant decrease in both hospitalization and pneumonia occurred in 2022 vs 2020. In our largest series of NEN patients with COVID-19, the NEN population is similar to the general population of patients with NEN regardless of COVID-19. However, older age, non-GEP primary sites and diabetes mellitus should be carefully considered for increased COVID-19 morbidity and mortality. Relevant information could be derived by integrating our results with NENs patients included in other cancer patients with COVID-19 registries.
